TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a Phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers
ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a Phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers
Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer
Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer
PROTECT™, A Novel Trispecific Antibody Masking Platform With Integrated Immune Modulation Displays Unique Activity and Differentiated Modes of Action
PROTECT™, A Novel Trispecific Antibody Masking Platform With Integrated Immune Modulation Displays Unique Activity and Differentiated Modes of Action
ZW251, a novel Glypican 3-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
ZW251, a novel Glypican 3-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
ZW171, a T Cell-Engaging, Bispecific Antibody for the Treatment of Mesothelin-Expressing Solid Tumors
ZW171, a T Cell-Engaging, Bispecific Antibody for the Treatment of Mesothelin-Expressing Solid Tumors
TriTCE CPI, Next Generation Trispecific T Cell Engagers with Integrated Checkpoint Inhibition (CPI) for the Treatment of Solid Tumors
TriTCE CPI, Next Generation Trispecific T Cell Engagers with Integrated Checkpoint Inhibition (CPI) for the Treatment of Solid Tumors
ZW270, A Conditionally Masked IL-12 Cytokine Fusion Protein Displaying Potent Anti-tumour Activity Absent of Systemic Toxicity
ZW270, A Conditionally Masked IL-12 Cytokine Fusion Protein Displaying Potent Anti-tumour Activity Absent of Systemic Toxicity
ZW191, a novel FRα-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
ZW191, a novel FRα-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery
Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker
stability and the primacy of payload delivery
ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Super-resolution imaging studies of zanidatamab: providing insights into its bispecific mode of action
Super-resolution imaging studies of zanidatamab: providing insights into its bispecific mode of action
